渤健Biogen (BIIB) 2022年年度报告「NASDAQ」.pdf

《渤健Biogen (BIIB) 2022年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen (BIIB) 2022年年度报告「NASDAQ」.pdf（192页珍藏版）》请在三个皮匠报告上搜索。

1、ANNUAL REPORT2022Safe harborThis letter contains forward-looking statements relating to:our strategy and plans;potential of,and expectations for,our commercial business and pipeline programs;capital allocation and investment strategy;clinical development programs,clinical trials,and data readouts an

2、d presentations;regulatory discussions,submissions,filings and approvals;the potential benefits,safety,and efficacy of our and our collaboration partners products and investigational therapies;the anticipated benefits and potential of investments,cost-saving initiatives,actions to improve risk profi

3、le and productivity of R&D pipeline,collaborations and business development activities;and our future financial and operating results.These forward-looking statements may be accompanied by such words as“aim,”“anticipate,”“believe,”“could,”“estimate,”“expect,”“forecast,”“goal,”“intend,”“may,”“plan,”“

4、potential,”“possible,”“prospect,”“will,”“would,”and other words and terms of similar meaning.Drug development and commercialization involve a high degree of risk,and only a small number of research and development programs result in commercialization of a product.Results in early-stage clinical tria

5、ls may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval.You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially fro

6、m those reflected in such statements,including:our dependence on sales from our products;uncertainty of long-term success in developing,licensing,or acquiring other product candidates or additional indications for existing products;failure to compete effectively due to significant product competitio